# Peptide Bioavailability Research 2026: Nasal, Transdermal, and Sublingual Delivery Methods
The history of peptide research has long been dominated by a single delivery route: subcutaneous or intravenous injection. This dominance is well-founded — injectable administration bypasses the gastrointestinal tract and achieves high, predictable bioavailability. But injection carries real limitations for researchers: the need for sterile technique, limited self-administration in animal models, discomfort in human protocols, and the practical challenge of repeated dosing in chronic research designs.
Alternative delivery routes — nasal, transdermal, and sublingual — have attracted research interest precisely because they offer paths around these limitations. In 2026, each of these routes has a distinct scientific profile, a maturing set of enabling technologies, and a growing evidence base from preclinical and early clinical research. This article examines what the current science says about each route, where the breakthroughs are emerging, and what researchers need to understand when evaluating non-injectable peptide administration.
---
The Bioavailability Problem: Route-by-Route
Bioavailability — the fraction of an administered dose that reaches systemic circulation in active form — is the central metric for evaluating any delivery route. Understanding why each alternative route has historically underperformed injections sets the stage for appreciating current advances.
Nasal route: The nasal mucosa provides a relatively permeable surface with an extensive blood supply and, crucially, direct connections to the olfactory and trigeminal nerves that bypass the blood-brain barrier (the "nose-to-brain" pathway). However, nasal bioavailability for peptides is typically limited by mucociliary clearance (which removes deposited material within 15–20 minutes), enzymatic degradation by nasal mucosal enzymes, and limited absorption for peptides larger than approximately 1,000 Da. Without formulation aids, most peptides achieve only 1–10% nasal bioavailability.
Transdermal route: The skin is designed as a barrier, and it is extraordinarily effective at its job. The stratum corneum — the outermost layer of dead keratinocytes embedded in a lipid matrix — excludes most molecules larger than 500 Da and most polar molecules. Peptides are both large and polar, making transdermal delivery without physical disruption of the skin essentially impossible for anything beyond small lipophilic peptides.
Sublingual route: The floor of the mouth is covered with a relatively thin, highly vascularized mucosa that lacks the thick mucus layer and enzymatic activity of the GI tract. Sublingual absorption enters the systemic circulation directly (bypassing hepatic first-pass metabolism via the sublingual vein), which represents a theoretical advantage. However, the small absorptive area, short residence time (as swallowed saliva constantly dilutes and removes the dose), and enzymatic activity of oral fluids limit practical bioavailability.
The enabling technologies described below are specifically designed to overcome these route-specific barriers.
---
Nasal Peptide Delivery: Science and 2026 Advances
The Nose-to-Brain Pathway
The most scientifically distinctive aspect of nasal peptide delivery is the nose-to-brain pathway. The olfactory nerve fibers that carry sensory signals from the nose to the brain are among the few places where the peripheral nervous system is in direct apposition with the central nervous system, with only a thin basement membrane separating nasal-side space from brain-side space.
Peptides deposited on the olfactory epithelium (located in the upper nasal cavity) can be transported along olfactory nerve axons to the olfactory bulb and then into deeper brain structures. This is not circulatory transport — it is direct axonal transport, and it can deliver meaningful concentrations to the CNS without first entering systemic circulation and crossing the blood-brain barrier.
The trigeminal pathway provides a secondary nose-to-brain transport route through the trigeminal nerve fibers that innervate the nasal mucosa and communicate directly with brainstem structures. Together, olfactory and trigeminal pathways make the nose uniquely positioned as a portal for brain-targeted peptide delivery.
This has major implications for peptide research in CNS areas: insulin, neuropeptide Y, oxytocin, IGF-1, and GLP-1 analogs have all been studied via nasal delivery specifically to target brain effects while minimizing peripheral exposure.
Absorption Enhancers for Nasal Delivery
Several classes of penetration enhancers have been evaluated for improving nasal peptide bioavailability:
Chitosan: A positively charged polysaccharide derived from chitin, chitosan adheres to the negatively charged nasal mucosa (mucoadhesion) and transiently opens epithelial tight junctions through electrostatic interactions. A nasal powder formulation of calcitonin gene-related peptide (CGRP) using 1% chitosan as a mucoadhesive polymer was developed for migraine treatment, showing nasal-to-brain delivery with effective pharmacodynamic effects in preclinical models.
Cell-penetrating peptides (CPPs): Short cationic or amphiphilic peptides that facilitate transcellular transport can be co-formulated with therapeutic peptides to improve nasal mucosal uptake. Several CPP-therapeutic peptide conjugates are in preclinical evaluation for nasal delivery.
Tight junction modulators: Specific peptides derived from zonula occludens proteins can transiently open tight junctions with higher selectivity than broad-spectrum permeation enhancers. These modulators represent a more targeted approach to paracellular permeation enhancement with potentially better safety profiles.
Chitosan-modified PLGA nanoparticles: Combining the mucoadhesive properties of chitosan with the controlled-release characteristics of PLGA polymer nanoparticles achieves extended residence time on the nasal mucosa, allowing more time for absorption before mucociliary clearance removes the dose.
Nasal Insulin: The Research Paradigm Case
Intranasal insulin has been studied more extensively than almost any other nasal peptide. The rationale is specific: nasal delivery can achieve meaningful brain insulin concentrations via the nose-to-brain pathway while producing minimal systemic insulin exposure (avoiding hypoglycemia). Since insulin receptors are expressed throughout the brain and regulate cognition, neuroplasticity, and metabolism, nasal insulin represents a potential treatment for insulin resistance in the brain — which has been implicated in Alzheimer's disease and other neurodegenerative conditions.
Multiple clinical trials of nasal insulin for Alzheimer's disease prevention and cognitive enhancement have been conducted, with mixed results. The SNIFF (Study of Nasal Insulin to Fight Forgetfulness) trials used a standard commercial nasal device and showed some cognitive signals in specific subpopulations. The INTREPAD study similarly found selective effects. Improved intranasal formulations using mucoadhesive enhancers and precision deposition devices are now in clinical evaluation.
Calcitonin and Desmopressin: Established Nasal Peptide Therapeutics
It is worth noting that nasal peptide delivery is not purely theoretical — two peptide drugs are already approved and in widespread clinical use via nasal administration.
Calcitonin nasal spray (Miacalcin): FDA-approved for osteoporosis, this 32-amino acid peptide achieves approximately 25% bioavailability via nasal administration compared to subcutaneous injection, sufficient for therapeutic bone resorption inhibition.
Desmopressin nasal spray (DDAVP): This synthetic vasopressin analog is approved for diabetes insipidus and nocturnal enuresis, achieving effective plasma concentrations through nasal delivery in millions of patients globally.
These approvals demonstrate that nasal peptide delivery can work reliably in clinical populations and provides precedent for regulatory evaluation of new nasal peptide formulations.
---
Transdermal Peptide Delivery: Overcoming the Skin Barrier
Why the Stratum Corneum Is Such a Formidable Barrier
The stratum corneum is approximately 15–20 µm thick and composed of dead corneocytes embedded in a lamellar lipid matrix (ceramides, cholesterol, fatty acids). Its barrier function is so effective that it limits transdermal flux for most drugs to biologically insignificant levels. For peptides, which are larger and more polar than most small-molecule drugs, passive transdermal transport is essentially zero.
Overcoming this barrier requires either chemical means (disrupting the lipid matrix) or physical means (creating channels through the stratum corneum). Both approaches have made substantial progress.
Microneedle Technology
Microneedles represent the most transformative development in transdermal peptide delivery. These arrays of microscale projections (typically 50–800 µm in height) penetrate the stratum corneum to create transient microchannels without reaching the underlying dermis nerves — making them essentially painless.
Four types of microneedle systems are in research use:
Solid microneedles (skin pretreatment): Applied to create channels, then removed; a conventional patch is applied over the pretreated skin. This "poke and patch" approach increased transdermal peptide flux by 10–1,000-fold in preclinical models.
Coated microneedles: The peptide payload is coated onto microneedle surfaces and dissolves upon skin insertion. This approach achieves precise dosing without dead volume and has shown particular promise for vaccine delivery and peptide hormone administration.
Hollow microneedles: Essentially microscale hypodermic needles that deliver liquid formulations directly through the skin. More technically complex to manufacture but capable of delivering higher peptide volumes.
Dissolving microneedles: The needles themselves are made from biocompatible polymers (PVP, PVA, gelatin, hyaluronic acid) loaded with peptide payload. Upon insertion, the needles dissolve into the skin, releasing the peptide while the backing is removed. This approach eliminates sharps waste and simplifies administration.
2026 research context: Dissolving microneedle patches for insulin, parathyroid hormone (PTH), and GLP-1 analogs have demonstrated proof-of-concept in preclinical and early clinical studies. Pharmacokinetic profiles from microneedle administration of insulin show onset-of-action comparable to subcutaneous injection with similar bioavailability in porcine skin models.
A key practical advantage for research: microneedle patches can be self-applied by study subjects without injection training, opening possibilities for ambulatory research designs that would be impractical with traditional injection protocols.
Chemical Enhancement Strategies
For researchers who cannot use microneedle devices, chemical penetration enhancers (CPEs) can modestly improve transdermal peptide flux through several mechanisms:
Fatty acid penetration enhancers (oleic acid, linoleic acid): These unsaturated fatty acids fluidize the stratum corneum lipid matrix by disrupting lamellar ordering, creating transient pathways for polar molecule permeation. Effective for small peptides (< 1,500 Da); limited utility for larger peptides.
Terpene-based enhancers: D-limonene, menthol, and other terpenes interact with lipid bilayer components to reduce barrier function. Combinations of terpenes with surfactants achieve greater flux enhancement than either alone.
Supersaturation strategies: Formulating peptides in a thermodynamically supersaturated state (high concentration relative to equilibrium solubility) increases the chemical potential driving diffusion through the skin. Polymer-peptide systems that maintain supersaturation in the formulation and at the skin surface have shown 5–15-fold increases in transdermal flux for model compounds.
Iontophoresis and Electroporation
Electrical methods for transdermal delivery have a long research history and remain relevant for peptide delivery:
Iontophoresis: Application of a low-level electric current (0.1–1 mA/cm²) electroosmotically drives solute transport across the skin. The technique is particularly effective for charged peptides and can achieve sustained, rate-controlled delivery. A transdermal iontophoresis patch for vasopressin has been demonstrated in animal models with essentially complete bioavailability relative to subcutaneous administration.
Sonophoresis (ultrasound): Low-frequency ultrasound (< 100 kHz) creates acoustic cavitation in the stratum corneum that transiently disrupts its lamellar structure, creating aqueous channels for hydrophilic macromolecule transport. The technique can be combined with chemical enhancers for additive effects.
Electroporation: Brief, high-voltage pulses (10–500 µs, 50–500 V) create electropores in both the stratum corneum lipid matrix and keratinocyte membranes, enabling transient macromolecule transport. Electroporation achieves the highest transient flux of any physical method but requires specialized equipment and produces moderate local skin irritation.
---
Sublingual Peptide Delivery: Science and Emerging Evidence
The Anatomy of Sublingual Absorption
The sublingual mucosa (floor of the mouth) and buccal mucosa (inner cheeks) have several properties that distinguish them from the GI mucosa:
- •Lack of digestive enzymes: Unlike the small intestine, the oral mucosa does not secrete proteases designed for nutrient digestion, though salivary aminopeptidases and other enzymes are present
- •Thin mucus layer: Less mucus than the intestinal mucosa, reducing entrapment of dissolved peptides
- •Direct venous drainage: Absorption from the floor of the mouth enters the sublingual veins, which drain to the lingual and facial veins and ultimately to the internal jugular vein — bypassing the portal circulation and hepatic first-pass metabolism
- •High vascularity: The sublingual region is richly vascularized, supporting rapid absorption of dissolved molecules
The primary limitation remains residence time: swallowing behavior and continuous salivary flow remove material from the sublingual space within minutes. Mucoadhesive formulations are essential to extend contact time.
Evidence for Sublingual Peptide Delivery
A 2024 study published in a peer-reviewed pharmaceutical journal demonstrated sublingual delivery of a GLP-1 analog using a novel carrier system. The study reported that superior formulations with certain mucoadhesive polymer carriers showed comparable onset, potency, and duration of action to subcutaneous administration, indicating enhanced sublingual delivery was possible. This proof-of-concept study directly compared pharmacokinetic profiles and pharmacodynamic effects between sublingual and subcutaneous routes.
Oxytocin, a 9-amino acid cyclic peptide with significant neuroscience research applications, has been evaluated via sublingual delivery as an alternative to intranasal administration. The rationale is that sublingual oxytocin may achieve different plasma/brain distribution profiles compared to nasal delivery. Several published studies report meaningful plasma oxytocin concentrations following sublingual administration in healthy subjects.
Cyclosporine (an 11-amino acid cyclic peptide) has long been formulated for oral administration, and investigations of sublingual delivery have shown promise in immunocompromised patients with GI absorption problems — validating that the sublingual route can achieve therapeutic exposure for peptide compounds.
Formulation Requirements for Sublingual Peptides
Effective sublingual peptide formulations must address several requirements simultaneously:
Mucoadhesion: The formulation must adhere to the sublingual mucosa long enough for peptide dissolution and absorption to occur. Mucoadhesive polymers used include hydroxypropyl methylcellulose (HPMC), carbopol/carbomer, sodium carboxymethylcellulose (NaCMC), and hyaluronic acid.
Rapid dissolution: Despite needing mucoadhesion, the peptide must dissolve rapidly from the formulation matrix to reach the mucosal surface in soluble form within the brief window before swallowing occurs.
Protease protection: Salivary enzymes (primarily aminopeptidases and endopeptidases) are active in the oral cavity. Cyclodextrin complexation, nanoparticle encapsulation, or direct enzyme inhibitor inclusion can reduce degradation during the absorption window.
pH optimization: The optimal pH for sublingual absorption of most peptides is near physiological (6.5–7.5), and formulation buffering systems must account for the buffer capacity of saliva while avoiding irritating pH extremes.
---
Comparing Routes: A Framework for Researchers
When selecting a non-injectable delivery route for peptide research, the following framework helps structure the decision:
Choose nasal when:
- •CNS effects are the target (nose-to-brain pathway)
- •Systemic bioavailability of 10–25% is sufficient for the planned dose
- •Rapid onset (within 30–60 minutes) is important
- •The peptide is ≤ 1,500 Da and reasonably polar
- •Direct brain/CSF delivery is important to isolate CNS from peripheral effects
Choose transdermal when:
- •Sustained, controlled-release delivery over 12–72 hours is needed
- •Avoiding GI tract and hepatic first-pass is a priority
- •The research design requires non-invasive, self-administered protocols
- •Microneedle devices are available and the peptide can be formulated at sufficient patch concentration
- •Local dermal effects (such as cosmetic peptide research) are the target
Choose sublingual when:
- •Rapid systemic absorption is desired with hepatic first-pass bypass
- •The peptide is small enough to dissolve quickly from mucoadhesive formulation
- •CNS delivery is not specifically needed
- •The research design requires non-injected administration in a clinical population
- •Comparison to oral (swallowed) administration is a research question
For detailed guidance on reconstitution and handling of injectable peptides (the current standard for most research), see our guides on how to reconstitute peptides and peptide storage best practices.
---
The Integration of Multiple Routes: Combination Approaches
A 2025–2026 trend is combining delivery routes for complementary benefits. Several research programs are evaluating:
Nasal priming + transdermal maintenance: A nasal dose provides rapid CNS effects via nose-to-brain pathway, while a transdermal patch delivers a sustained lower dose for peripheral effects over 24 hours.
Sublingual onset + oral sustained release: A sublingual tablet provides rapid absorption for the first 30 minutes, then a conventional enteric-coated oral tablet is swallowed for continued delivery through the GI tract.
Microneedle + iontophoresis combination: Sequential application of microneedle pretreatment (creating channels) followed by iontophoresis patches achieves higher transdermal flux than either technique alone for larger peptides.
---
Regulatory Considerations
Non-injectable peptide delivery routes face additional regulatory scrutiny compared to established injection routes. Key considerations for researchers:
Bioequivalence demonstration: Regulatory agencies require demonstration of bioequivalence (AUC, Cmax within 80–125% of reference) or pharmacodynamic equivalence when switching from injectable to non-injectable routes. This typically requires dedicated clinical PK studies.
Excipient safety: Penetration enhancers, mucoadhesive polymers, and other formulation excipients require their own safety evaluation. Several nasal penetration enhancers previously thought to be safe have raised concerns about long-term mucosal irritation with chronic use.
Device qualification: Nasal sprays, transdermal patches, and sublingual formulations are combination products (drug + device) in most regulatory frameworks. Device qualification requirements add complexity to regulatory submissions.
For context on the regulatory landscape for research peptides more broadly, see our guide to the research peptide regulatory landscape.
---
Summary for Researchers
1. Nasal delivery is most advanced for CNS-targeted peptides via the nose-to-brain pathway, with chitosan-based mucoadhesive systems and targeted olfactory deposition improving efficiency; bioavailability typically 10–25% systemically but potentially much higher for brain-targeted effects
2. Transdermal delivery via dissolving microneedle patches is approaching practical research use for insulin, GLP-1 analogs, and growth factors, with pharmacokinetics comparable to subcutaneous injection in preclinical models
3. Sublingual delivery offers hepatic first-pass bypass with rapid onset for small peptides (< 1,500 Da); mucoadhesive formulations dramatically improve performance over simple solution administration
4. Iontophoresis remains a viable option for transdermal delivery of charged peptides with specialized equipment
5. Route selection should be driven by target (CNS vs peripheral), required pharmacokinetics (rapid onset vs sustained), peptide size, and research design constraints
6. Combination approaches are emerging as the most sophisticated research use of alternative routes — combining nose-to-brain rapid effects with sustained systemic delivery
7. Absolute bioavailability data must be reported for all alternative routes; comparative claims without reference to injectable standards are insufficient for rigorous research interpretation
---
This article is for educational and research purposes only. Delivery technologies and research compounds discussed have not been approved for human therapeutic use except where specifically noted.
---
Nanoparticle-Enhanced Alternative Route Delivery
One of the most active research areas in 2025–2026 is the combination of nanoparticle carriers with alternative delivery routes, creating synergistic systems that address multiple barriers simultaneously.
Lipid Nanoparticles for Nasal Delivery
Solid lipid nanoparticles (SLNs) and lipid nanocarriers applied intranasally achieve two simultaneous goals: protection from nasal enzymatic degradation (the lipid matrix provides a protective microenvironment) and improved mucosal uptake (through interaction of lipid surfaces with nasal mucosal membranes). For insulin delivered intranasally via SLNs, systemic bioavailability as high as 7–12% has been reported — 3–5-fold improvement over insulin solution — in preclinical studies.
Chitosan-coated lipid nanoparticles combine mucoadhesion (from chitosan) with enzymatic protection (from the lipid core), addressing both residence time and stability simultaneously. The coating strategy is now being applied to multiple peptide payloads including exenatide, calcitonin, and insulin-like growth factor-1 (IGF-1).
Self-Assembling Peptide Nanostructures
An elegant approach to alternative route peptide delivery uses the peptides themselves to form the delivery vehicle. Self-assembling peptide nanofibers and hydrogels that respond to pH, ionic strength, or enzymatic activity can create depot formulations suitable for transdermal or sublingual application.
Peptide amphiphiles — peptides conjugated to lipid tails that assemble into cylindrical nanofibers — have been used to create dermal depots that slowly release bioactive peptide payload over 24–72 hours. The depot persists at the application site rather than distributing systemically immediately, creating a sustained release profile analogous to a subcutaneous depot injection but without the needle.
For broader context on self-assembling peptide systems, see our article on self-assembling peptides: from nanofibers to hydrogels.
---
Half-Life Considerations in Alternative Route Research
When designing research protocols using non-injectable delivery routes, pharmacokinetic considerations become even more important than with standard injectable administration.
Absorption phase dominance: For alternative routes with slow or variable absorption (transdermal, sublingual), the absorption phase can dominate the observed pharmacokinetic profile in ways that make it difficult to isolate intrinsic peptide half-life from absorption-rate effects. True elimination half-life measurements require IV administration in separate experiments.
Bioavailability-dependent Cmax: Unlike subcutaneous injection (80–100% bioavailability, predictable Cmax), alternative routes produce highly variable peak concentrations depending on formulation quality, application technique, and individual anatomical variation. Research designs must account for this variability through larger sample sizes or within-subject controls.
First-pass bypass effects: Nasal and transdermal routes bypass hepatic first-pass metabolism, which means the ratio of parent compound to metabolites in systemic circulation differs from oral (swallowed) administration. When comparing alternative routes to oral administration, metabolite profiles must be considered.
Peptide half-life modification interacts with route selection: Long-acting peptides (semaglutide, 168 hours) have such extended half-lives that the route-specific differences in absorption kinetics become less clinically relevant — once steady-state is achieved, plasma concentration is dominated by elimination, not absorption. Conversely, short-acting peptides (native GLP-1, oxytocin) may require continuous or highly frequent alternative route administration to maintain therapeutic concentrations.
For fundamental pharmacokinetic concepts relevant to peptide research, see our comprehensive peptide half-life reference guide.